Company: BDRX
Filing Date: 2025-11-17
Form Type: POS AM
Source: 0001214659-25-016826
Chunk: 16

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-11-17
Form: POS AM
Chunk 16
---
 under the heading “Cautionary Statement Regarding Forward-Looking Statements” herein.

The sale of a substantial amount of our Ordinary Shares (represented by Depositary Shares), including resale of the Ordinary Shares (represented by Depositary Shares) issuable upon the exercise of the warrants held by the selling shareholders in the public market could adversely affect the prevailing market price of our Ordinary Shares and/or Depositary Shares.

We are registering for
resale 171,700,000 Ordinary Shares represented by 1,717 Depositary Shares issuable upon the exercise of warrants held by the selling
shareholders. Sales of substantial amounts of our Ordinary Shares and/or Depositary Shares in the public market, or the perception that
such sales may occur, could adversely affect the market price of our Ordinary Shares and/or Depositary Shares. We cannot predict if and
when selling shareholders may sell such shares in the public markets. Furthermore, in the future, we may issue additional Ordinary Shares
(including Ordinary Shares represented by Depositary Shares). Any such issuance could result in substantial dilution to our existing
shareholders and could cause our share price to decline.

| 9 |

<div align='center'>USE OF PROCEEDS</div>

We will not receive any
proceeds from the sale of the Ordinary Shares represented by Depositary Shares issuable upon the exercise of the December 2023 Private
Placement Pre-Funded Warrants by the selling shareholders. All net proceeds from the sale of the Ordinary Shares underlying the December
2023 Private Placement Pre-Funded Warrants covered by this prospectus will go to the selling shareholders. However, upon any exercise
of the December 2023 Private Placement Pre-Funded Warrants for cash, the applicable selling stockholder would pay us the exercise price
of $0.025 per share.

We expect that the selling
shareholders will sell their Ordinary Shares represented by Depositary Shares as described under “Plan of Distribution.”

| 10 |

<div align='center'>DIVIDEND POLICY</div>

Since
inception, we have never declared or paid any cash dividends on our Ordinary Shares and do not anticipate paying any cash dividends on
our Ordinary Shares or the Depositary Shares in the foreseeable future. We intend to retain all available funds and any future earnings
to fund the development and expansion of our business. As a result, investors in the Ordinary Shares and Depositary Shares will benefit
in the foreseeable future only if the Ordinary Shares and Depositary Shares appreciate in value.

Any
determination to